What Preclinical Research Shows About CJC-1295 (No DAC)

At a glance: CJC-1295 (No DAC) preclinical research summary

CJC-1295 (No DAC), also designated as Modified GRF (1-29), is a synthetic 29-amino acid peptide derivative modeled after endogenous Growth Hormone-Releasing Hormone (GHRH). Preclinical literature indicates that amino acid substitutions at positions 2, 8, 15, and 27 enhance resistance against rapid enzymatic cleavage by Dipeptidyl Peptidase-4 (DPP-IV) without altering native receptor specificity.

In cell culture assays and animal models, the compound demonstrates targeted affinity for GHRH receptors on anterior pituitary somatotrophs. Unlike its long-acting counterpart containing the Drug Affinity Complex (DAC), this variant exhibits a half-life of approximately 30 minutes in rodent models, permitting researchers to induce transient GH spikes that closely mimic physiological pulsatile secretion.

Investigators regularly utilize this reagent to evaluate growth factor cascades, downstream hepatic IGF-1 expression, cellular proliferation, and extracellular matrix remodeling in tissue repair assays. Maintaining analytical purity above 98% is critical for preventing non-specific receptor crosstalk during sensitive binding and receptor kinetics studies.

What is CJC-1295 (No DAC) and how does it function in vitro?

CJC-1295 (No DAC) was developed as an optimized fragment of native GHRH (1-44). The native peptide undergoes rapid systemic inactivation in biological media, primarily through DPP-IV cleavage between the Alanine-2 and Aspartate-3 residues. By substituting D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27, chemists created a tetrasubstituted analog with significantly increased enzymatic stability.

In vitro functional assays show that binding of this modified peptide to GHRH receptors activates the transmembrane Gs alpha subunit. This stimulation triggers intracellular adenylate cyclase, escalating cyclic adenosine monophosphate (cAMP) accumulation and opening voltage-gated calcium channels. The resulting intracellular calcium influx triggers the exocytosis of stored growth hormone vesicles from somatotrophic cells.

Because the peptide lacks the maleimidopropionic acid linker present in DAC-modified variants, it does not covalently bind to serum albumin. As a result, researchers studying `cjc no dac` observe rapid systemic clearance rather than continuous baseline elevation, making it an ideal molecular probe for experiments requiring discrete temporal control over GH exposure.

What do animal models reveal about GH and IGF-1 signaling?

Preclinical studies across rodent and non-human primate models highlight the specific endocrine responses elicited by GHRH analogs. When administered in controlled animal trials, `cjc 1295` without DAC induces immediate, high-amplitude secretagogue responses, driving circulating growth hormone concentrations to peak levels within 15 to 30 minutes post-exposure.

Following the initial GH peak, secondary signaling cascades stimulate hepatic gene expression of Insulin-like Growth Factor 1 (IGF-1) and its primary binding protein, IGFBP-3. IGF-1 acts as a primary mediator of cell growth, protein translation, and tissue regeneration across musculoskeletal and visceral organ models. Researchers monitoring these downstream markers note sustained IGF-1 elevation for several hours after the primary GH wave has cleared.

In models evaluating cellular regeneration, elevated IGF-1 concentrations secondary to GHRH stimulation are associated with increased satellite cell activation, accelerated collagen deposition, and improved cellular survival under ischemic or oxidative stress conditions. These findings position the peptide as a foundational reagent in regenerative biology and metabolic signaling research.

How does CJC-1295 (No DAC) compare to CJC-1295 With DAC?

When designing preclinical protocols, selecting between Modified GRF (1-29) and its albumin-bound variant depends entirely on the experimental model's requirement for secretagogue kinetics. Both peptides target identical GHRH receptors, but their pharmacokinetic profiles diverge substantially due to structural modification.

CJC-1295 with DAC includes a maleimidopropionic acid bioconjugate group that attaches to circulating serum albumin following exposure. This reaction extends the terminal half-life to several days in animal models, maintaining elevated baseline GH and IGF-1 levels continuously. While useful for studying sustained hormone exposure, continuous activation can lead to GHRH receptor desensitization or downregulation in long-term models.

Conversely, researchers who order 2 mg or 5 mg CJC-1295 (No DAC) vials utilize a tool that preserves natural pulsatile dynamics. The rapid clearance profile prevents continuous receptor occupancy, allowing researchers to evaluate repeated pulse-frequency dynamics without inducing receptor tachyphylaxis. For researchers comparing both options across comparative protocols, full technical specifications for both variants are listed within the PX1 research peptide catalog.

Why is the combination of GHRH and GHRP analogs studied together?

A substantial portion of published secretagogue literature focuses on the dual-activation of pituitary somatotrophs using synergistic peptide combinations. GHRH analogs operate through the cAMP/protein kinase A pathway, whereas Growth Hormone Secretagogue Receptor (GHSR-1a) agonists act via the phospholipase C and intracellular inositol trisphosphate (IP3) pathways.

Preclinical co-administration assays involving `cjc ipamorelin` demonstrate a synergistic release of GH that exceeds the additive calculations of either compound administered in isolation. In rodent models, simultaneous stimulation of both receptor pathways triggers amplified vesicle exocytosis while suppressing endogenous somatostatin signal inhibition.

To conduct multi-target endocrine experiments, researchers often source ipamorelin research vials alongside GHRH analogs to explore maximal secretory capacity, receptor cross-talk, and signal transduction cascades in isolated pituitary tissue culture or intact animal models.

Laboratory preparation, reconstitution, and reagent handling

To maintain structural integrity and prevent molecular degradation during laboratory work, lyophilized peptides must be stored and handled under strict environmental controls. Lyophilized CJC-1295 (No DAC) standardly arrives as a sterile, vacuum-sealed white powder and should be stored at -20°C prior to reconstitution.

For reconstitution, laboratory technicians should use sterile bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline depending on the requirements of the downstream assay. Reconstitution should be performed by gently running the solvent along the internal glass wall of the vial, followed by low-velocity rotational swirling. High-shear mechanical agitation or vigorous shaking must be avoided, as it can induce peptide denaturing or aggregation.

Once reconstituted, liquid aliquots should be maintained at 2°C to 8°C for short-term experimental usage or snap-frozen in single-use aliquots at -80°C for extended stability. Repeated freeze-thaw cycles should be avoided to prevent peptide chain cleavage and maintain consistent dosing accuracy across serial assay runs.

How to vet a research peptide supplier: Red flags to avoid

In vitro and preclinical research accuracy depends entirely on compound purity and consistency. Sourcing sub-standard reagents introduces uncontrollable variables, such as variable peptide concentration, trifluoroacetic acid (TFA) salts, bacterial endotoxins, or truncated amino acid impurities that corrupt assay data.

When auditing potential vendors for laboratory supply contracts, research institutions should avoid suppliers that exhibit the following industry red flags:

1. Missing or static Certificates of Analysis: Vendors providing generic COAs without batch-specific lot numbers, analytical HPLC chromatograms, or mass spectrometry spectra.

2. Lack of endotoxin quantification: Failure to conduct Limulus Amebocyte Lysate (LAL) testing to verify that bacterial endotoxin levels remain below 0.01 EU/mg, which is critical for preventing inflammatory artifacts in cell culture and animal models.

3. Opaque manufacturing and dispatch sourcing: Overseas dropshipping or re-labeling imported bulk material without domestic analytical re-verification and secure U.S. facility storage.

4. Non-compliant marketing: Vendors making consumer health claims, offering clinical dosing guidance, or presenting research chemicals as consumer treatments rather than strictly regulated laboratory reagents.

PX1 Research quality benchmarks vs. industry standards

PX1 Research establishes rigorous quality verification protocols to ensure every synthesized lot meets exact analytical standards before entering laboratory distribution.

- Purity Verification: Every batch of CJC-1295 (No DAC) undergoes High-Performance Liquid Chromatography (HPLC) to guarantee a minimum purity threshold of 98.0%, alongside Mass Spectrometry (MS) to confirm exact molecular weight.

- Endotoxin Testing: Quantitative LAL assays are performed per lot to verify low endotoxin content, protecting biological cultures from inflammatory contamination.

- Lot Traceability & COAs: Fully accessible, lot-specific COAs containing full spectral data are uploaded directly for buyer verification prior to dispatch.

- U.S. Synthesis & Storage: Synthesized under controlled conditions and stored in climate-controlled domestic distribution hubs in California and Arizona.

- Rapid Dispatch: Same-day shipping for domestic orders placed before cutoff times (Monday–Friday), ensuring minimal thermal exposure during transit.

- Technical Support: Dedicated support staff capable of providing detailed analytical documentation and order tracking for academic and industrial researchers.

Ordering CJC-1295 (No DAC) from PX1 Research

PX1 Research provides laboratory-grade CJC-1295 (No DAC) in standard 2 mg and 5 mg glass vials, formulated via solid-phase peptide synthesis (SPPS) and lyophilized under high vacuum to preserve long-term stability.

Orders fulfilled through PX1 Research ship directly from state-of-the-art dispatch centers in California and Arizona. Standard orders placed Monday through Friday before 2:00 PM local facility time are processed and dispatched the same day with tracked domestic transit options.

Each shipment includes batch-matched documentation enabling immediate verification of compound mass, purity profiles, and endotoxin metrics. To review full analytical testing data or buy pure CJC-1295 (No DAC) for research, visit the product listing or consult our technical team via the PX1 peptide research library.